[{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"fbc97175-6cf6-4bb7-91ab-e5923255e6ef","acronym":"ZN-c3-016","url":"https://clinicaltrials.gov/study/NCT05743036","created_at":"2023-02-24T16:01:19.641Z","updated_at":"2025-02-25T17:02:25.578Z","phase":"Phase 1","brief_title":"ZN-c3 in Adult Participants With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05743036 - ZN-c3-016","lead_sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • azenosertib (ZN-c3)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 09/25/2026","study_completion_date":" 09/25/2026","last_update_posted":"2025-02-03"},{"id":"c7ba05df-48e5-4170-b8f3-f78ce52e05e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05682170","created_at":"2023-01-12T15:02:24.531Z","updated_at":"2024-07-02T16:35:04.517Z","phase":"Phase 1/2","brief_title":"Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT05682170","lead_sponsor":"K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azenosertib (ZN-c3) • asaretoclax (ZN-d5)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-10"},{"id":"d3dd1e14-36e0-44ed-b491-b9afe3ad5f5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05198804","created_at":"2022-01-20T15:53:52.222Z","updated_at":"2024-07-02T16:35:45.369Z","phase":"Phase 1/2","brief_title":"A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT05198804","lead_sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • azenosertib (ZN-c3)"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 01/27/2022","start_date":" 01/27/2022","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-06-19"},{"id":"177f8b5d-8348-4b32-a118-0b00e538da2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05431582","created_at":"2022-06-24T15:56:46.001Z","updated_at":"2024-07-02T16:35:45.607Z","phase":"Phase 1","brief_title":"Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors","source_id_and_acronym":"NCT05431582","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CCNE1","pipe":" | ","alterations":" TP53 mutation • CCNE1 amplification • TP53 amplification","tags":["TP53 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CCNE1 amplification • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • azenosertib (ZN-c3)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 12/14/2022","primary_completion_date":" 12/14/2022","study_txt":" Completion: 12/14/2022","study_completion_date":" 12/14/2022","last_update_posted":"2023-06-15"},{"id":"60c6440d-4895-4fff-9eb4-94c308053c49","acronym":"NCI-2022-03599","url":"https://clinicaltrials.gov/study/NCT05368506","created_at":"2022-05-10T19:53:37.209Z","updated_at":"2024-07-02T16:35:48.992Z","phase":"Phase 1","brief_title":"ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer","source_id_and_acronym":"NCT05368506 - NCI-2022-03599","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" HER-2 • ER • PGR • CHEK1 • CDK1","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • CHEK1 • CDK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azenosertib (ZN-c3)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/30/2023","start_date":" 07/30/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2023-05-04"}]